International Assets Investment Management LLC Purchases Shares of 6,572 Lantheus Holdings, Inc. (NASDAQ:LNTH)

International Assets Investment Management LLC bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 6,572 shares of the medical equipment provider’s stock, valued at approximately $407,000.

Other large investors also recently added to or reduced their stakes in the company. Tucker Asset Management LLC raised its stake in Lantheus by 239.0% during the 3rd quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 282 shares during the period. First Horizon Advisors Inc. raised its stake in Lantheus by 97.0% during the 3rd quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 225 shares during the period. Covestor Ltd raised its stake in Lantheus by 62.7% during the 3rd quarter. Covestor Ltd now owns 527 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 203 shares during the period. Parkside Financial Bank & Trust raised its stake in Lantheus by 36.6% during the 3rd quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider’s stock valued at $40,000 after purchasing an additional 156 shares during the period. Finally, NBC Securities Inc. acquired a new stake in Lantheus during the 3rd quarter valued at $46,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently commented on LNTH. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a report on Saturday, January 13th. JMP Securities restated a “market outperform” rating and set a $100.00 price target on shares of Lantheus in a report on Friday, February 23rd. B. Riley boosted their price target on shares of Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a report on Thursday, April 18th. Finally, Truist Financial restated a “buy” rating and set a $82.00 price target (up from $80.00) on shares of Lantheus in a report on Monday, February 26th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $104.71.

Lantheus Trading Down 0.0 %

Shares of NASDAQ:LNTH opened at $65.20 on Friday. The stock has a market capitalization of $4.47 billion, a PE ratio of 14.05 and a beta of 0.53. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $100.85. The firm has a fifty day moving average price of $61.31 and a 200 day moving average price of $62.75. The company has a current ratio of 5.80, a quick ratio of 5.45 and a debt-to-equity ratio of 0.69.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.33 by $0.26. The firm had revenue of $354.00 million during the quarter, compared to analysts’ expectations of $350.44 million. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. Analysts expect that Lantheus Holdings, Inc. will post 5.96 EPS for the current fiscal year.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 93,863 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the completion of the sale, the director now directly owns 251,643 shares in the company, valued at $16,434,804.33. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the firm’s stock in a transaction on Wednesday, March 6th. The stock was bought at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the acquisition, the insider now directly owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Mary Anne Heino sold 93,863 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the sale, the director now owns 251,643 shares of the company’s stock, valued at $16,434,804.33. The disclosure for this sale can be found here. Insiders sold 94,545 shares of company stock worth $6,169,936 over the last ninety days. Company insiders own 1.50% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.